1 Metabolic Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland, USA.
2 Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
3 Diabetes, Endocrine, and Obesity Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland, USA.
4 Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
5 Developmental Therapeutics Branch, National Cancer Institute, National Institute of Health, Bethesda, Maryland, USA.
This letter to the editor responds to comments by Salinas and colleagues on experiences with identification of adrenal insufficiency among patients on immune checkpoint inhibitor therapy.